1. Date of occurrence of the event:2023/09/06
2. Company name : Diamond Biofund Inc.
3. Relationship to the Company (please enter ”head office” or subsidiaries”):Head office.
4. Reciprocal shareholding ratios : N/A
5. Cause of occurrence : Announcement for the underwriting price for cash capital increase before IPO.
6. Counter measures : None.
7. Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):

(1) The Company’s public underwriting of cash capital increase before the initial listing, 100,000 thousand common shares with par value of NT$10 and NT$1,000,000 thousand in total, has been declared effective by Taiwan Stock Exchange Corporation on 2023/08/02 in the official letter No.1121803660.

(2) This cash capital increase will be issued with a premium price. The minimum underwriting price of the competitive auction is NT$37.74 per share. Securities shall be awarded on the basis of bid price in descending order, and each successful bidder shall subscribe the securities at the bidder’s own bid price. The weighted average of the bid price of all successful bids is NT$47.18, which is higher than 1.06 times of the minimum underwriting price, so the underwriting price is determined to be issued with a premium at NT$40 per share.

(3) The newly issued common shares of this cash capital increase are non-physical shares, and their rights and obligations are the same as the existing common shares.